A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
09/2011
09/09/2011	WO2011108521A1 Mucosal vaccine
09/09/2011	WO2011107957A1 Anti-her2 antibodies and compositions
09/09/2011	WO2011107883A1 Avian group d rotavirus
09/09/2011	WO2011107586A1 Smoc1, tenascin-c and brain cancers
09/09/2011	WO2011107534A1 Recombinant attenuated parvovirus
09/09/2011	WO2011107520A1 Expression of monoclonal antibodies in ciliate host cells
09/09/2011	WO2011107507A1 Biparatopic abeta binding polypeptides
09/09/2011	WO2011107480A1 Antigen binding proteins specific for serum amyloid p component
09/09/2011	WO2011106981A1 Use of cytokine-superantigen fusion protein for preparing medicament against solid tumor
09/09/2011	WO2011106885A1 Oligomer-specific amyloid beta epitope and antibodies
09/09/2011	WO2011085103A3 Plasma kallikrein binding proteins
09/09/2011	WO2011083091A3 Methods for treating pancreatic cancer
09/09/2011	WO2011079308A3 Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
09/09/2011	WO2011053937A3 Antibody mimetic scaffolds
09/09/2011	WO2011053565A3 Compositions and methods for detecting a tauopathy
09/09/2011	WO2011050299A3 Adenovirus infection in animals
09/09/2011	WO2011050222A3 Therapeutic compositions that disrupt the hydrogen bonded ring structure in gp41 and methods for treating hiv
09/09/2011	WO2011050152A3 Site-specific modification of proteins
09/09/2011	CA2828131A1 Expression of monoclonal antibodies in ciliate host cells
09/09/2011	CA2811091A1 A method for inhibiting alternative pathway mediated disorders with anti-properdin antibodies that inhibit c5 interactions with properdin
09/09/2011	CA2792161A1 Ep1 inhibition
09/09/2011	CA2792034A1 Avian rotavirus
09/09/2011	CA2791962A1 Methods and compositions for treating degos' disease
09/09/2011	CA2791866A1 Monoclonal antibodies directed to cd52
09/09/2011	CA2791850A1 Molecular clone of hiv-1
09/09/2011	CA2791685A1 Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
09/09/2011	CA2791676A1 Prognostic marker for cryoglobulinemic vasculitis and b cell malignancies in hcv infected patients
09/09/2011	CA2791661A1 Mucosal vaccines
09/09/2011	CA2791658A1 Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
09/09/2011	CA2791648A1 Antibody specific for apolipoprotein and methods of use thereof
09/09/2011	CA2791631A1 Therapeutic dll4 binding proteins
09/09/2011	CA2791560A1 Monoclonal antibodies directed to cd20
09/09/2011	CA2791538A1 Oligomer-specific amyloid beta epitope and antibodies
09/09/2011	CA2790653A1 Recombinant attenuated parvovirus
09/09/2011	CA2789557A1 Antigen binding proteins specific for serum amyloid p component
09/09/2011	CA2788289A1 Methods for screening antibodies
09/09/2011	CA2788275A1 Biparatopic abeta binding polypeptides
09/08/2011	US20110219464 Lung disease targets and uses thereof
09/08/2011	US20110218333 Internalizing ErbB2 antibodies
09/08/2011	US20110218329 Anti-il-6 antibodies, compositions, methods and uses
09/08/2011	US20110217772 Animal protein free media for cultivation of cells
09/08/2011	US20110217757 Modified vaccinia ankara virus variant and cultivation method
09/08/2011	US20110217749 Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
09/08/2011	US20110217376 Poly(amidoamine) oligomer hydrogel for drug delivery and drug carrier using the same
09/08/2011	US20110217366 Immunopotentiating composition
09/08/2011	US20110217363 Two-step targeted tumor therapy with prodrug encapsulated in nanocarrier
09/08/2011	US20110217356 Controlled delivery system
09/08/2011	US20110217338 HIV-1 Envelope Based Fragments
09/08/2011	US20110217334 Hypoallergenic molecules
09/08/2011	US20110217333 Soft gel delivery system for treating poultry
09/08/2011	US20110217332 Chimpanzee Adenovirus Vaccine Carriers
09/08/2011	US20110217331 Inactivation of Reverse Transcriptases By Azido-diarylpyrimidines
09/08/2011	US20110217330 Novel method
09/08/2011	US20110217329 Vaccine
09/08/2011	US20110217328 Compositions and methods for treating ebola virus infection
09/08/2011	US20110217327 Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs
09/08/2011	US20110217326 Method for diagnosing and/or treating tumor
09/08/2011	US20110217325 T cell epitopes of the cyn d 1 allergen from bermuda grass pollen
09/08/2011	US20110217323 Imidazoquinoline compounds
09/08/2011	US20110217322 Automated Vaccination Method and System
09/08/2011	US20110217321 Antibody drug conjugates (adc) that bind to 161p2f10b proteins
09/08/2011	US20110217320 Hapten-carrier conjugates for treating and preventing nicotine addiction
09/08/2011	US20110217319 Methods of use of sialoadhesin factor-2 antibodies
09/08/2011	US20110217318 Anti-platelet membrane glycoprotein vi monoclonal antibody
09/08/2011	US20110217317 Treatment of thrombocytopenia
09/08/2011	US20110217316 GBS Toxin Receptor Compositions and Methods of Use
09/08/2011	US20110217315 Methods and compositions for risk prediction, diagnosis, prognosis, and treatment of pulmonary disorders
09/08/2011	US20110217314 Methods and Compositions for Modulating Apoptosis
09/08/2011	US20110217313 Treatment of orthopedic conditions
09/08/2011	US20110217312 Targeting poly-gamma-glutamic acid to treat staphylococcus epidermidis and related infections
09/08/2011	US20110217311 Cycloalkyl containing thienopyrimidines for pharmaceutical compositions
09/08/2011	US20110217310 Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology
09/08/2011	US20110217309 Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
09/08/2011	US20110217308 Compositions and methods using recombinant MHC molecules for the treatment of stroke
09/08/2011	US20110217307 Synthetic peptides corresponding to overlapping neutralizing determinants in the cbd1 epitope induce broadly neutralizing antibodies
09/08/2011	US20110217306 C-terminal exon 5.4 of runx1/aml1
09/08/2011	US20110217305 Anti-her2 antibodies and compositions
09/08/2011	US20110217304 Monoclonal antibodies directed to cd52
09/08/2011	US20110217303 Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
09/08/2011	US20110217302 TCR Complex Immunotherapeutics
09/08/2011	US20110217301 Methods for treating or screening for compounds for the treatment of sepsis
09/08/2011	US20110217300 Quinazolinone Compounds and Methods of Use Thereof
09/08/2011	US20110217299 Targeting pax2 for the treatment of breast cancer
09/08/2011	US20110217298 Monoclonal antibodies directed to cd20
09/08/2011	US20110217297 Methods for classifying and treating breast cancers
09/08/2011	US20110217296 Method for selecting patients for treatment with an egfr inhibitor
09/08/2011	US20110217295 Treatment of lupus arthritis using laquinimod
09/08/2011	US20110217294 Combination of hgf inhibitor and hedgehog inhibitor to treat cancer
09/08/2011	US20110217293 Uses of morelloflavone
09/08/2011	US20110217292 Monoclonal antibodies against hmgb1
09/08/2011	US20110217291 Soluble hybrid fct receptors and related methods
09/08/2011	US20110217290 Treatment and/or prevention of peanut induced anaphylaxis
09/08/2011	US20110217289 Melt-Coated Dosage Forms
09/08/2011	US20110217288 Involvement of Androgen/Androgen Receptor Pathway in Fabry Disease
09/08/2011	US20110217270 Methods for treating tumors and cancerous tissues
09/08/2011	US20110217259 IL-16 as a target for diagnosis and therapy of hematological malignancies and solid tumors
09/08/2011	US20110217244 Compositions and methods for enhancing immune response
09/08/2011	US20110217237 Therapeutic dll4 binding proteins
09/08/2011	US20110217232 Method for Determination of the Responsiveness of an Individual to Misletoe Lectin
09/08/2011	US20110217231 Anti-tenascin monoclonal antibody therapy for lymphoma

1 ... 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 ... 1823